Alison Hiong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alison Hiong has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Malaka Ameratunga
Department of Medical Oncology Alfred Health Melbourne Australia
3 shared publications Adam H. Lapidus
Department of Oncology, Alfred Health, Melbourne, Victoria, Australia
1 shared publicationAjay Raghunath
Department of Medical Oncology Austin Health Heidelberg Australia
1 shared publicationAlison Y. Zhang
Deparmtent of Medical Oncology Chris O'Brien Lifehouse Camperdown Australia
1 shared publicationAndrew Weickhardt
Department of Medical Oncology Austin Health Heidelberg Australia
1 shared publicationAngelyn Anton
Department of Urology Eastern Health Box Hill Australia
1 shared publication
Latest Publications
- Open Access
- 7 March 2026
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 7 (5) , 100978
Treatment Timeliness in Extensive-Stage SCLC and Impact on Survival: A Registry-Based Observational Study
- 7 March 2026
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 7 (5) , 100978
Open AccessTreatment Timeliness in Extensive-Stage SCLC and Impact on Survival: A Registry-Based Observational Study
- 3 February 2026
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 54 (3) , 355-366
Uveal Melanoma Treatment: An Update
Uveal melanoma is a rare malignancy arising from uveal tract melanocytes. Definitive treatment options for primary disease include plaque brachytherapy, proton beam radiotherapy and enucleation, which provide high rates of local control, but are associated with vision impairment, reduced quality of life and unsatisfactorily high rates of metastatic relapse. In the metastatic setting, average life expectancy remains less than 2 years, despite the availability of immune checkpoint inhibitors and the more recent arrival of the T cell‐engaging agent, tebentafusp. Here, we provide an update regarding the current treatment of uveal melanoma, and discuss the potential roles of novel targeted therapies, immunotherapy and neoadjuvant therapy in shaping future management.
- 3 February 2026
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 54 (3) , 355-366
Uveal Melanoma Treatment: An Update
Uveal melanoma is a rare malignancy arising from uveal tract melanocytes. Definitive treatment options for primary disease include plaque brachytherapy, proton beam radiotherapy and enucleation, which provide high rates of local control, but are associated with vision impairment, reduced quality of life and unsatisfactorily high rates of metastatic relapse. In the metastatic setting, average life expectancy remains less than 2 years, despite the availability of immune checkpoint inhibitors and the more recent arrival of the T cell‐engaging agent, tebentafusp. Here, we provide an update regarding the current treatment of uveal melanoma, and discuss the potential roles of novel targeted therapies, immunotherapy and neoadjuvant therapy in shaping future management.
- Open Access
- 15 September 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (9)
Perioperative chemotherapy use and related outcomes in muscle‐invasive bladder cancer in Australia
Objectives: To explore Australian data on perioperative chemotherapy use and associated outcomes in muscle‐invasive bladder cancer (MIBC).Subjects and Methods: An observational study of patients with MIBC treated with neoadjuvant chemotherapy, adjuvant chemotherapy or surgery alone was conducted using data from BLADDA, a multicentre Australian urothelial cancer registry. Pathological response to neoadjuvant chemotherapy and its effect on event‐free survival (EFS) and overall survival (OS) were determined. EFS and OS in patients who underwent neoadjuvant chemotherapy, adjuvant chemotherapy or surgery alone were compared using univariate and multivariable proportional hazards regression.Results: From 2018 to 2024, 259 patients enrolled in the BLADDA registry met inclusion criteria, of which 45% received neoadjuvant chemotherapy, 23% received adjuvant chemotherapy, 1.2% received both neoadjuvant and adjuvant chemotherapy and 31% underwent surgery only. The proportion of patients treated with neoadjuvant chemotherapy increased over time. A total of 21 of 67 (31%) evaluable subjects achieved a pathological complete response, which was associated with improved EFS and OS. Excluding patients who received both neoadjuvant and adjuvant chemotherapy, the EFS hazard ratio (HR) was 0.43 (95% confidence interval [CI] 0.29–0.65, p < 0.001) for neoadjuvant chemotherapy and 0.59 (95% CI 0.38–0.94, p = 0.03) for adjuvant chemotherapy compared to surgery alone. Neoadjuvant chemotherapy was associated with prolonged OS in the univariate analysis (HR 0.43, 95% CI 0.26–0.73, p = 0.002) but not in the multivariable analysis (HR 0.59, 95% CI 0.32–1.08, p = 0.09). OS was not improved with adjuvant chemotherapy (unadjusted HR 0.76, 95% CI 0.44–1.31, p = 0.3; adjusted HR 0.86, 95% CI 0.46–1.60, p = 0.6).Conclusion: Neoadjuvant chemotherapy use for MIBC in Australia has increased over the past decade, but it remains underutilised. This has important implications as perioperative chemo‐immunotherapy emerges as a standard of care. Although a clear impact on survival in the overall population was not observed, this was potentially due to the limited sample size.
- 15 September 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (9)
Open AccessPerioperative chemotherapy use and related outcomes in muscle‐invasive bladder cancer in Australia
Objectives: To explore Australian data on perioperative chemotherapy use and associated outcomes in muscle‐invasive bladder cancer (MIBC).Subjects and Methods: An observational study of patients with MIBC treated with neoadjuvant chemotherapy, adjuvant chemotherapy or surgery alone was conducted using data from BLADDA, a multicentre Australian urothelial cancer registry. Pathological response to neoadjuvant chemotherapy and its effect on event‐free survival (EFS) and overall survival (OS) were determined. EFS and OS in patients who underwent neoadjuvant chemotherapy, adjuvant chemotherapy or surgery alone were compared using univariate and multivariable proportional hazards regression.Results: From 2018 to 2024, 259 patients enrolled in the BLADDA registry met inclusion criteria, of which 45% received neoadjuvant chemotherapy, 23% received adjuvant chemotherapy, 1.2% received both neoadjuvant and adjuvant chemotherapy and 31% underwent surgery only. The proportion of patients treated with neoadjuvant chemotherapy increased over time. A total of 21 of 67 (31%) evaluable subjects achieved a pathological complete response, which was associated with improved EFS and OS. Excluding patients who received both neoadjuvant and adjuvant chemotherapy, the EFS hazard ratio (HR) was 0.43 (95% confidence interval [CI] 0.29–0.65, p < 0.001) for neoadjuvant chemotherapy and 0.59 (95% CI 0.38–0.94, p = 0.03) for adjuvant chemotherapy compared to surgery alone. Neoadjuvant chemotherapy was associated with prolonged OS in the univariate analysis (HR 0.43, 95% CI 0.26–0.73, p = 0.002) but not in the multivariable analysis (HR 0.59, 95% CI 0.32–1.08, p = 0.09). OS was not improved with adjuvant chemotherapy (unadjusted HR 0.76, 95% CI 0.44–1.31, p = 0.3; adjusted HR 0.86, 95% CI 0.46–1.60, p = 0.6).Conclusion: Neoadjuvant chemotherapy use for MIBC in Australia has increased over the past decade, but it remains underutilised. This has important implications as perioperative chemo‐immunotherapy emerges as a standard of care. Although a clear impact on survival in the overall population was not observed, this was potentially due to the limited sample size.
- 1 September 2024
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 129, 110816
Herpes zoster in patients with glioma treated with temozolomide
- 1 September 2024
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 129, 110816
Herpes zoster in patients with glioma treated with temozolomide
- 17 October 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 8 (4) , 325-330
Globe Salvage and Vision Preservation by Neoadjuvant Darovasertib and Crizotinib in Uveal Melanoma
- 17 October 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 8 (4) , 325-330
Globe Salvage and Vision Preservation by Neoadjuvant Darovasertib and Crizotinib in Uveal Melanoma
- 7 March 2016
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 14 (4) , 425-433
Sepsis following cancer surgery: the need for early recognition and standardised clinical care
Despite the implementation of multimodal bundles of care in hospitalised patients, post-operative sepsis in patients with cancer still accounts for a significant burden of illness and substantial healthcare costs. Patients undergoing surgery for cancer are at particular risk of sepsis due to underlying malignancy, being immunocompromised associated with cancer management and the complexity of surgical procedures performed. In this review, we evaluate the burden of illness and risks for sepsis following surgery for cancer. Current evidence supporting standardised strategies for sepsis management (including early recognition and resuscitation) is examined together with challenges in implementing quality improvement programs.
- 7 March 2016
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 14 (4) , 425-433
Sepsis following cancer surgery: the need for early recognition and standardised clinical care
Despite the implementation of multimodal bundles of care in hospitalised patients, post-operative sepsis in patients with cancer still accounts for a significant burden of illness and substantial healthcare costs. Patients undergoing surgery for cancer are at particular risk of sepsis due to underlying malignancy, being immunocompromised associated with cancer management and the complexity of surgical procedures performed. In this review, we evaluate the burden of illness and risks for sepsis following surgery for cancer. Current evidence supporting standardised strategies for sepsis management (including early recognition and resuscitation) is examined together with challenges in implementing quality improvement programs.